Skip to main content
. 2019 Jun 11;8(7):935–940. doi: 10.1530/EC-19-0272

Table 1.

Comparison of secondary outcomes by treatment group.

Parameter Group n = 80 (total) P value
Oestradiol alone (N = 21) Cyproterone (N = 21) Spironolactone (N = 38)
Urea (mmol/L) 4.9 (4.2–5.8) 4.2 (3.6–5.1) 5.0 (4.3–6.0) 0.035
Creatinine (µmol/L) 78 (72–96) 72 (63–75) 77 (69–85) 0.069
Oestradiol valerate dose (mg) 6 (4–6) 5 (4–6) 6 (4–6) 0.601
Oestradiol concentration (pmol/L) 256 (119–408) 279 (149–334) 279 (233–384) 0.795
BMI (kg/m2) 27.2 (23.1–31.9) 24.5 (23.4–30.3) 24.7 (23.5–31.0) 0.989
Systolic BP (mmHg) 125 (121–131) 123 (118–136) 125 (120–136) 0.941
Diastolic BP (mmHg) 80 (75–81) 85 (80–90) 80 (75–82) 0.056
Haemoglobin (g/L) 147 (143–159) 148 (143–151) 146 (138–158) 0.880
ALT (U/L) 21 (15–28) 23 (15–29) 19 (14–24) 0.630

Median (IQR) are presented. P values refer to overall difference between the groups and are obtained from the Kruskal–Wallis test as a non-parametric alternative to t-test.